Newly Developed Modified Diluted Prothrombin Time Reagent: A Multi-Centre Validation in Patients with Non-Valvular Atrial Fibrillation under Direct Oral Anticoagulant Therapy.

In recent years, direct oral anticoagulants (DOACs) that target thrombin and factor Xa have been developed, and DOACs have many advantages over vitamin K antagonists (VKA). The use of DOACs without the routine monitoring and frequent dose adjustment has been shown to be safe and effective in the majority of patients making them more convenient anticoagulants than VKA [1–3]. However, it was reported that the measurement of DOACs effects would be required in the clinical circumstances of specific patients with renal impairment, liver disease, low residual coagulation activity or major bleeding [4].